Tiziana Life Sciences Share Discussion Threads

[jpuff] 11/6/2022 21:49

Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS PatientSource: GlobeNewswire Inc.Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today announces an interview with Chief Executive Officer and Chief Scientific Officer Kunwar Shailubhai, PhD and Proactive Investors discussing the positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program at the Brigham and Women's Hospital (BWH), Boston, MA.About Foralumab Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2?c-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was not only well tolerated but it also produced strong clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

[ic0gcds00] 11/6/2022 06:50

See latest rns

[ic0gcds00] 11/6/2022 06:50

No See latest rns

[one_frankel] 08/6/2022 14:36

Lean likes to be cryptic but if you figure it out, the key awaits to the road of riches FHasson!

[lean5gb] 08/6/2022 11:58

........ ... .. (chuckle)

[one_frankel] 03/6/2022 12:29

Ohh that old chestnut Puff!...Yes, patience, patience and some more everlasting patience!

[jpuff] 01/6/2022 19:59

It'll recover, patience needed

[one_frankel] 01/6/2022 16:17

The funny thing is that even my older and seemingly wiser uncle who was so believing of Tils potential has come to the dire conclusion that it is nothing more than a scam!

[jpuff] 01/6/2022 14:05

Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

[jpuff] 31/5/2022 20:02

Added a few more

[michelle74] 30/5/2022 13:14

Yes big scam

[fandagle] 28/5/2022 06:43

Can we all agree now that this has been a ponsy scam?

[twodegrees] 27/4/2022 13:15

ACCUSTEM SCIENCES - Notification of Receipt of Entitlements
Acquisition by Accustem Sciences Inc (US Accustem).

1 New share of US Accustem Common stock for every Existing 20 shares of Accustem Sciences Ltd (UK Accustem) Ordinary shares held.

Based on your holding of 1758 ACCUSTEM SCIENCES ORD GBP0.01 shares you have received 87 ACCUSTEM SCIENCE.I USD0.001 shares.

On 2nd November 2021 the board of directors of UK Accustem announced a proposal to establish US Accustem as the holding company of the Accustem Group.

The Acquisition, which was conducted by way of a Scheme of Arrangement, received shareholder approval at a General Meeting and Court approval at a Court Meeting both held on 18th November 2021. The Scheme was then Court sanctioned at a Court Hearing held on 25th November 2021 and subsequently became effective on 29th November 2021.

We can confirm that the New US Accustem shares have now been credited to your account and your Existing UK Accustem shares have been removed.

No fractions of shares have been issued. Any resulting cash entitlements will be dealt with in accordance with our Terms & Conditions.

Please be aware that the New US Accustem shares have been admitted to trading on the US OTC Market. As a result we will only be able to facilitate sales in the US Accustem shares via our sharedealing facility.

Should you wish to find more information about the Scheme, please visit the Company website, www.accustem.com/

[jpuff] 27/4/2022 08:39

Riley Financial Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)Source: TipRanksB.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Tiziana Life Sciences (TLSA – Research Report) today and set a price target of $3.00. The company's shares closed last Wednesday at $1.04. According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -21.8% and a 28.5% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on Tiziana Life Sciences is a Moderate Buy with an average price target of $3.00.https://www.tipranks.com/news/blurbs/b-riley-financial-sticks-to-their-buy-rating-for-tiziana-life-sciences-tlsa?utm_source=advfn.com&utm_medium=referral

[jpuff] 27/4/2022 08:30

Enjoy the Fireside chat laddie

[fandagle] 27/4/2022 07:45

Good Grief Is this TaT still trading?

[jpuff] 26/4/2022 17:34

Yes and the ticker is tlsa over on the Nasdaq. Not to be confused with the slightly larger company ticker tsla which is Tesla.

[breezy4] 26/4/2022 17:17

Is this trading??

[jpuff] 26/4/2022 16:37

Had an email from Tiziana to say they're partaking in a fireside chat. Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

[alancapone] 26/4/2022 05:33

"The stock market is a device for transferring money from the impatient to the patient."

[marshsi] 25/4/2022 22:57

Sold out of this scam today.
Put it behind me.
Complete sham.
Still left with a piece of paper with ACUT shares on. Broker won’t touch it.

[nerdofsteel] 14/4/2022 15:03

LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce its uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”). AccuStem will commence trading on the OTCQB at the market open today, April 14, 2022, under the ticker “ACUT.” The Company believes that the uplist will create greater visibility to retail and institutional investors, as well as further enhance trading liquidity.

[one_frankel] 11/4/2022 18:39

1Macosta, when you're emailing either party, CC the other so they're aware of the situation at hand and will hopefully be able to resolve it with the joint effort.